Eli Lilly (LLY)

Is this the best way to cash in on the weight-loss gold rush?

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026.

It's worth sticking with the stock through the hard times.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.8% in the afternoon session after a major competitor, Novo Nordisk, announced that its experimental obesity drug failed to show it was as effective as Lilly's tirzepatide in a head-to-head clinical trial. 

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

WASHINGTON D.C. — In a dramatic shift of the global economic landscape, the United States is currently witnessing a massive "repatriation" of industrial capacity, commonly referred to as the US Manufacturing Renaissance. As of February 23, 2026, over $3 trillion in reshoring-related investments have been announced since early 2025, driven

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a single session. The massive sell-off, which erased approximately $100 billion in market capitalization, was triggered

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.

Hedge funds bet heavily on big tech, Eli Lilly, and others in Q4, driving flows into SPY, QQQ, as mega-cap stocks dominated portfolio allocations.

The stock looks unstoppable.

Eli Lilly shares climb after Novo Nordisk trial miss. CagriSema trails tirzepatide in 84-week weight-loss study results.

Microsoft flagged that services that require Multi-Factor Authentication may return gateway timeout errors for users in the U.S.

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the "personalized medicine" movement, the company is currently grappling with extreme stock volatility following a series of aggressive regulatory maneuvers and high-stakes litigation [...]

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing clinical data from its primary rival, Novo Nordisk (NYSE: NVO), which announced that its highly anticipated next-generation weight-loss drug,

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated Phase 3 trial results for its next-generation obesity treatment, CagriSema. The data from the REDEFINE 4 study revealed that the drug,

The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website.

Novo Nordisk investors get a second bite at the Ozempic apple.

Novo's next-gen drug CagriSema didn't match weight loss from Eli Lilly's Zepbound.

Viking stock has plenty of room to run.